LUDWIG INSTITUTE FOR CANCER RESEARCH
Patent Owner
Stats
- 295 US PATENTS IN FORCE
- 5 US APPLICATIONS PENDING
- Jan 30, 2018 most recent publication
Details
- 295 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 6,552 Total Citation Count
- Feb 25, 1985 Earliest Filing
- 320 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0145,391 TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEINFeb 02, 17May 25, 17[C12Q, C12P, C12N, G01N, C07K]
2017/0008,976 ANTI-METALLOPROTEASE ANTIBODY FOR DIAGNOSIS AND TREATMENT OF CANCERSFeb 04, 15Jan 12, 17[G01N, C07K]
2016/0272,976 PRODUCTS AND METHODS FOR TREATMENT OF FAMILIAL AMYOTROPHIC LATERAL SCLEROSISAug 26, 14Sep 22, 16[A61K, C12N]
2013/0289,253 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USESep 30, 11Oct 31, 13[C07K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9700532 iNKT cell modulators and methods of using the sameMay 12, 16Jul 11, 17[A61J, A61K, C07C, C07K]
9534258 Devices and methods for prognosis prediction for melanoma cancerAug 29, 14Jan 03, 17[C07H, C12Q, C12P]
9518112 TGF-β1 specific antibodies and methods and uses thereofMar 06, 13Dec 13, 16[A61K, G01N, C07K]
9487579 Methods and compositions for modulation of blood-neural barrierMay 20, 14Nov 08, 16[A61K, C07K]
9469678 NY-ESO-1 peptides which bind to class II molecules and uses thereofMar 01, 04Oct 18, 16[A61K, C07K]
9314515 Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancersApr 22, 09Apr 19, 16[A61K, G01N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0237,432 METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPTAbandonedOct 14, 14Aug 18, 16[C12N]
2014/0255,436 IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENSAbandonedApr 07, 14Sep 11, 14[A61K]
2014/0120,099 TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEINAbandonedSep 24, 13May 01, 14[C12Q, C12N]
2014/0050,780 LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOFAbandonedDec 22, 11Feb 20, 14[A61K]
2013/0224,249 RECOMBINANT TRYPANOSOMA CRUZI CELLS USEFUL AS ANTI-CANCER IMMUNE AGENTSAbandonedSep 01, 11Aug 29, 13[A61K, C12N]
2013/0039,910 METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITIONAbandonedApr 13, 12Feb 14, 13[A61K, A61P]
2013/0029,358 IMMUNODOMINANT MHC DR52B RESTRICTED NY-ESO-1 EPITOPES, MHC CLASS II MONOMERS AND MULTIMERS, AND USES THEREOFAbandonedOct 01, 10Jan 31, 13[G01N, C07K]
8357373 Methods for stimulating an immune response using bacterial antigen delivery systemExpiredOct 03, 06Jan 22, 13[A61K, A01N]
8354243 Method for determining presence of cancer in a sample by assaying for expression of ECSA/DPPA-2 nucleotide sequencesExpiredOct 02, 07Jan 15, 13[G01N]
2013/0011,496 CANCER TESTIS ANTIGENS AS BIOMARKERS IN NON-SMALL CELL LUNG CANCERAbandonedNov 23, 10Jan 10, 13[A61K, C12Q, G01N, A61P, C40B]
2012/0328,660 IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENSAbandonedMay 31, 12Dec 27, 12[A61K, A61P]
2012/0238,478 PROTEIN MARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF OVARIAN AND BREAST CANCERAbandonedMay 04, 12Sep 20, 12[C40B, C07K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.